The main finding in this investigation of patients with a recent acute coronary syndrome and newly diagnosed dysglycaemia was that (i) seven months of treatment with the SGLT2i empagliflozin improved insulin sensitivity indexes; (ii) changes in those insulin sensitivity indexes were correlated with changes in cardiac volumes as measured by CMR after seven months of empagliflozin therapy; (iii) the impact of empagliflozin was not long-lasting as revealed by the findings from three months after cessation of the drug. This evidence concerns the gene INS and acute coronary syndrome.